INTSINTENSITY THERAPEUTICS, INC.
$4.81
$0.11
(2.34%)
Pre-Market
Reported EarningsMay 7
Mkt Cap$12.84M
Vol1,069.00
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...
PR Newswire
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR...
PR Newswire
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...
PR Newswire
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...
PR Newswire
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update PR Newswire SHELTON, Conn., March 27, 2026 Raised over $20 million in gross...
PR Newswire
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US PR Newswire SHELTON, Conn...
PR Newswire
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest INTS News
ViewIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
PR Newswire
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
PR Newswire
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Zacks
MSTR9
18
ORCL54
34
SPCX16
9Advertisement|Remove ads.